Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
Launched by MINGGE LLC · Dec 16, 2022
Trial Information
Current as of January 16, 2025
Active, not recruiting
Keywords
ClinConnect Summary
BACKGROUND:
The extent of glioma resection is directly related to patient survival, and a combination of multiple imaging and molecular pathology imaging methods has been developed to achieve maximum safe resection. In this study, three types of data, preoperative magnetic resonance imaging, intraoperative ultrasound and molecular genotype, will be collected and combined to build an artificial intelligence imaging model to achieve maximum safe resection and prolong patient's life.
PLAN:
In order to achieve the goal of maximum safe resection, we plan to sequentially implement imaging-base...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age over 18 years old
- • Tumor in non-functional areas of the cerebral hemisphere.
- • Preoperative diagnosis of glioma.
- • Undergo glioma removal surgery.
- Exclusion Criteria:
- • Postoperative confirmation of non-glioma.
- • Magnetic resonance or ultrasound data not available.
Trial Officials
Zhifeng Shi, DM
Study Director
Huashan Hospital
Jinhua Yu, DE
Study Chair
Fudan University
Yinhui Deng, DE
Principal Investigator
Fudan University
About Mingge Llc
Mingge LLC is a dynamic clinical trial sponsor dedicated to advancing innovative therapeutic solutions through rigorous scientific research. With a focus on enhancing patient outcomes, the company specializes in designing and managing clinical trials across various therapeutic areas, leveraging cutting-edge methodologies and technology-driven approaches. Mingge LLC is committed to fostering collaborative partnerships with healthcare professionals, research institutions, and regulatory bodies, ensuring adherence to the highest standards of ethics and compliance. Through its comprehensive expertise and a patient-centered approach, Mingge LLC aims to contribute significantly to the development of safe and effective treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials